Home › Funds › Parkman Healthcare Partners LLC › BCRX

Parkman Healthcare Partners LLC position in BCRX

BIOCRYST PHARMACEUTICALS INC · Health Care

Parkman Healthcare Partners LLC reported holding 1,624,279 shares of BCRX (BIOCRYST PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$16.2M, representing 1.66% of its reported portfolio and ranking #24 among its reported holdings. Parkman Healthcare Partners LLC has disclosed BCRX holdings in 9 of the last 9 reported quarters, going back to Q2 2024.

Latest position (Q2 2026)1.62M sh
Reported value held$16.24M
Portfolio Weight1.66%
First reportedQ2 2024
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Parkman Healthcare Partners LLC's BCRX position evolved

Parkman Healthcare Partners LLC first disclosed a stake in BCRX in Q2 2024 at 400,448 shares (US$2.5M). The position peaked in Q1 2026 at 1,708,099 shares, worth US$16.3M. Across 9 filings, Parkman Healthcare Partners LLC increased the stake 4 time(s), trimmed it 3 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 1,624,279 shares valued at US$16.2M — a reduction of -83,820 shares quarter over quarter.. Notable position changes include a 53% trim in Q4 2024 (shares were roughly flat over the following quarter), a 361% increase in Q1 2025 (shares rose 19% over the following quarter), a 90% increase in Q1 2026 (shares rose 5% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2024 400.45K $2.47M New
Q3 2024 464.05K $3.53M Add
Q4 2024 216.88K $1.63M Reduce
Q1 2025 1.00M $7.50M Add
Q2 2025 1.01M $9.03M Add
Q3 2025 1.01M $7.69M Hold
Q4 2025 900.06K $7.02M Reduce
Q1 2026 1.71M $16.26M Add
Q2 2026 1.62M $16.24M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BCRX and 13F data

BCRX (BIOCRYST PHARMACEUTICALS INC) is a Health Care company. 46 other funds we track also report a position in BCRX — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$158.3M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$151.0M), TCG Crossover Management, LLC (US$110.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BCRX

All BCRX fund holders →

FAQ

How long has Parkman Healthcare Partners LLC held BCRX?

Parkman Healthcare Partners LLC has disclosed BCRX holdings in 9 of the last 9 reported quarters, going back to Q2 2024.

What is Parkman Healthcare Partners LLC's current position in BCRX?

As of Q2 2026, Parkman Healthcare Partners LLC holds 1.62M shares of BCRX (BIOCRYST PHARMACEUTICALS INC), valued at $16.24M, representing 1.66% of its reported portfolio and ranking #24.

Has Parkman Healthcare Partners LLC been buying or selling BCRX?

In the latest 13F filing (Q2 2026), Parkman Healthcare Partners LLC reduced its position in BCRX. The position peaked in Q1 2026 at 1.71M shares.

Which other funds hold BCRX?

Other major institutional holders of BCRX include RA CAPITAL MANAGEMENT, L.P., DEERFIELD MANAGEMENT COMPANY, L.P., TCG Crossover Management, LLC, among 46 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.